Merck & Co. Inc. (NYSE:MRK) reported results from the TECOS cardiovascular outcomes trial (CVOT) of Januviasitagliptin, which Merck had previously said met the study's primary endpoint of non-inferiority
Read the full 298 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury